Showing 1691-1700 of 4063 results for "".
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Results Published From 2-year Multicenter Study Illustrate Efficacy and Safety of Preserflo MicroShunthttps://modernod.com/news/results-published-from-2-year-multicenter-study-illustrate-efficacy-and-safety-of-preserflo-microshunt/2480287/Santen EMEA has announced the results from a 2-year multicenter study of the Preserflo MicroShunt in patients with primary open-angle glaucoma (POAG). The study showed that mean IOP was significantly reduced from 21.7±3.4 mmHg at baseline to 14.1±3.2 mmHg at year 2 (&
- Regeneron Announces Topline Phase 2 Data of High-Dose Aflibercept in Wet AMDhttps://modernod.com/news/regeneron-announces-topline-phase-2-data-of-high-dose-aflibercept-in-wet-amd/2479468/Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients
- Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/Palatin Technologies announced positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visi
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- Palatin Technologies Completes Enrollment of Phase 2 Study for Dry Eye Disease Treatment Candidatehttps://modernod.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/Palatin Technologies announced completion of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 phase 2 clinical study in subjects
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferenceshttps://modernod.com/news/meiragtx-to-present-clinical-data-from-phase-1-2-trial-of-aav-rpe65-at-upcoming-scientific-conferences/2476861/MeiraGTx Holdings announced that clinical data updates from the company’s phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The phase 1/2 open-label, multicenter, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with diseas